Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

103 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
mTOR and regulation of energy homeostasis in humans.
Mannaa M, Krämer S, Boschmann M, Gollasch M. Mannaa M, et al. J Mol Med (Berl). 2013 Oct;91(10):1167-75. doi: 10.1007/s00109-013-1057-6. Epub 2013 Jun 12. J Mol Med (Berl). 2013. PMID: 23756767 Review.
Normobaric hypoxic conditioning in men with metabolic syndrome.
Klug L, Mähler A, Rakova N, Mai K, Schulz-Menger J, Rahn G, Busjahn A, Jordan J, Boschmann M, Luft FC. Klug L, et al. Among authors: boschmann m. Physiol Rep. 2018 Dec;6(24):e13949. doi: 10.14814/phy2.13949. Physiol Rep. 2018. PMID: 30565412 Free PMC article. Clinical Trial.
Lifestyle interventions in Muslim patients with metabolic syndrome-a feasibility study.
Aktas MF, Mähler A, Hamm M, Perger G, Simon F, Westenhöfer J, Luft FC, Boschmann M. Aktas MF, et al. Among authors: boschmann m. Eur J Clin Nutr. 2019 May;73(5):805-808. doi: 10.1038/s41430-018-0371-z. Epub 2018 Dec 11. Eur J Clin Nutr. 2019. PMID: 30538299 Clinical Trial.
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
Mähler A, Mandel S, Lorenz M, Ruegg U, Wanker EE, Boschmann M, Paul F. Mähler A, et al. EPMA J. 2013 Feb 18;4(1):5. doi: 10.1186/1878-5085-4-5. EPMA J. 2013. PMID: 23418936 Free PMC article.
Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
Mähler A, Steiniger J, Bock M, Klug L, Parreidt N, Lorenz M, Zimmermann BF, Krannich A, Paul F, Boschmann M. Mähler A, et al. Am J Clin Nutr. 2015 Mar;101(3):487-95. doi: 10.3945/ajcn.113.075309. Epub 2015 Jan 14. Am J Clin Nutr. 2015. PMID: 25733633 Clinical Trial.
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Engeli S, May M, Nussberger J, Danser AHJ, Dole WP, Prescott MF, Dahlke M, Stitah S, Pal P, Boschmann M, Jordan J. Engeli S, et al. J Am Soc Hypertens. 2017 Aug;11(8):488-497. doi: 10.1016/j.jash.2017.06.002. Epub 2017 Jun 12. J Am Soc Hypertens. 2017. PMID: 28666704 Clinical Trial.
Atrial natriuretic peptide and adiponectin interactions in man.
Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, Jordan J. Birkenfeld AL, et al. PLoS One. 2012;7(8):e43238. doi: 10.1371/journal.pone.0043238. Epub 2012 Aug 16. PLoS One. 2012. PMID: 22916229 Free PMC article.
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM, Prescott MF, Dahlke M, Jordan J. Boschmann M, et al. J Hypertens. 2012 Mar;30(3):561-6. doi: 10.1097/HJH.0b013e32834f6b43. J Hypertens. 2012. PMID: 22278138 Clinical Trial.
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Janke J, et al. J Hypertens. 2006 Sep;24(9):1809-16. doi: 10.1097/01.hjh.0000242405.68461.84. J Hypertens. 2006. PMID: 16915030
103 results
Jump to page